Ally Bridge Group’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Ally Bridge Group’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-170,000	Closed	-$4.5M	–	47
2022 Q2	$4.5M	Hold	170,000	–	–	4.1%	10
2022 Q1	$5.95M	Buy	+170,000	New	+$4.96M	4.41%	9
2021 Q3	–	Sell	-675,670	Closed	-$17.3M	–	36
2021 Q2	$17.3M	Sell	675,670 -1,052,920	-61%	-$15.1M	4.3%	8
2021 Q1	$23.7M	Sell	1,728,590 -38,850	-2%	-$568K	4.55%	4
2020 Q4	$29.3M	Buy	+1,767,440	New	+$23M	5.02%	5

Other funds holding CERE

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Ally Bridge Group's CERE Position: Q3 2022 in Review

Ally Bridge Group sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2022, closing a stake of 170,000 shares — an estimated $4.5M sold.

Ally Bridge Group first reported a position in CERE in Q4 2020 and held it in 5 quarters. The position peaked at $29.3M in Q4 2020. 114 funds tracked by Wall St. Rank hold CERE as of Q3 2022.

Ally Bridge Group reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Ally Bridge Group sold 170,000 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2022, an estimated $4.5M.
Ally Bridge Group first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 5 quarters.
Ally Bridge Group's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $29.3M in Q4 2020.
114 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2022.

Based on Ally Bridge Group's 13F filing for Q3 2022, filed 14 Nov 2022.